The Effect of Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NASH
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
Price : $35 *
At a glance
- Drugs Ezetimibe (Primary) ; Ursodeoxycholic acid (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.